Physician profile
Darrell S Rigel
NPI 1740217033
$101,884.42
in general payments reported to CMS, 2019-2025
27 companies · $29K in 2025
The $29K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,750 · 2020: $471 · 2021: $559 · 2022: $1,498 · 2023: $23K · 2024: $39K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $6,183 · Travel and Lodging: $3,463 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $59,950.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,410.00 |
| Food and Beverage | $6,183.28 |
| Travel and Lodging | $3,463.11 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $51,940.04 | 2019-2025 | Odomzo |
| Pfizer INC. | $33,626.33 | 2021-2025 | |
| Almirall LLC | $6,874.79 | 2019-2025 | Seysara, Klisyri |
| Biofrontera INC. | $2,149.92 | 2025 | |
| Novartis Pharmaceuticals Corporation | $819.90 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $732.59 | 2019-2023 | Siliq |
| Galderma Laboratories, L.P. | $681.66 | 2019-2025 | |
| Lilly USA, LLC | $635.49 | 2021-2023 | Taltz |
| Allergan, INC. | $625.00 | 2019 | |
| Incyte Corporation | $590.93 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Pharmaceuticals, INC. | $571.08 | 2019 | |
| Dermavant Sciences, INC. | $461.52 | 2023-2024 | Vtama |
| Ucb, INC. | $416.31 | 2022-2024 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $394.25 | 2022-2024 | Dupixent, Libtayo |
| Leo Pharma INC. | $281.06 | 2022-2025 | Anzupgo, Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $227.01 | 2022-2023 | Sotyktu |
| Dermira, INC. | $169.99 | 2020 | |
| Abbvie INC. | $146.99 | 2025 | |
| Epi Health, LLC | $123.47 | 2022 | |
| Genentech USA, INC. | $89.86 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $67.34 | 2020 | |
| Amgen INC. | $52.89 | 2020 | |
| Celgene Corporation | $52.89 | 2020 | |
| Genentech, INC. | $47.95 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Genzyme Corporation | $33.29 | 2025 | |
| Glenmark Therapeutics INC. | $33.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Rigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.